SI
ZNTL icon

Scharf Investments’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Scharf Investments’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-7,531
Closed -$212K – 54
2023
Q2 		$212K Buy
+7,531
New +$181K 0.01% 51

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Scharf Investments's ZNTL Position: Q3 2023 in Review

Scharf Investments sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2023, closing a stake of 7,531 shares — an estimated $212K sold.

Scharf Investments first reported a position in ZNTL in Q2 2023 and held it in 1 quarter. The position peaked at $212K in Q2 2023. 137 funds tracked by Wall St. Rank hold ZNTL as of Q3 2023.

  • Scharf Investments reported no remaining Zentalis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Scharf Investments sold 7,531 Zentalis Pharmaceuticals shares in Q3 2023, an estimated $212K.
  • Scharf Investments first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Scharf Investments's Zentalis Pharmaceuticals position peaked at $212K in Q2 2023.
  • 137 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2023.

Based on Scharf Investments's 13F filing for Q3 2023, filed 13 Oct 2023.